Free Trial

MyHealthChecked (MHC) Competitors

MyHealthChecked logo
GBX 7.66 -0.10 (-1.23%)
As of 11:57 AM Eastern

MHC vs. AVO, RUA, SUN, POLX, BELL, MXCT, DEMG, SN, NIOX, and EKF

Should you be buying MyHealthChecked stock or one of its competitors? The main competitors of MyHealthChecked include Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), Surgical Innovations Group (SUN), Polarean Imaging (POLX), Belluscura (BELL), MaxCyte (MXCT), Deltex Medical Group (DEMG), Smith & Nephew (SN), NIOX Group (NIOX), and EKF Diagnostics (EKF). These companies are all part of the "medical devices" industry.

MyHealthChecked vs. Its Competitors

Advanced Oncotherapy (LON:AVO) and MyHealthChecked (LON:MHC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

MyHealthChecked has higher revenue and earnings than Advanced Oncotherapy. MyHealthChecked is trading at a lower price-to-earnings ratio than Advanced Oncotherapy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanced OncotherapyN/AN/A-£32.60M-£0.07N/A
MyHealthChecked£3.22M1.24-£1.04M-£3.76-2.04

Advanced Oncotherapy has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500. Comparatively, MyHealthChecked has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500.

In the previous week, MyHealthChecked's average media sentiment score of 0.13 beat Advanced Oncotherapy's score of 0.00 indicating that MyHealthChecked is being referred to more favorably in the news media.

Company Overall Sentiment
Advanced Oncotherapy Neutral
MyHealthChecked Neutral

Advanced Oncotherapy has a net margin of 0.00% compared to MyHealthChecked's net margin of -11.06%. MyHealthChecked's return on equity of -12.80% beat Advanced Oncotherapy's return on equity.

Company Net Margins Return on Equity Return on Assets
Advanced OncotherapyN/A -67.34% -11.73%
MyHealthChecked -11.06%-12.80%-8.18%

17.8% of Advanced Oncotherapy shares are owned by institutional investors. Comparatively, 0.7% of MyHealthChecked shares are owned by institutional investors. 47.5% of Advanced Oncotherapy shares are owned by insiders. Comparatively, 9.3% of MyHealthChecked shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

MyHealthChecked beats Advanced Oncotherapy on 7 of the 11 factors compared between the two stocks.

Get MyHealthChecked News Delivered to You Automatically

Sign up to receive the latest news and ratings for MHC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MHC vs. The Competition

MetricMyHealthCheckedMedical Devices IndustryMedical SectorLON Exchange
Market Cap£3.98M£2.60B£6.11B£2.57B
Dividend YieldN/A2.45%5.72%5.38%
P/E Ratio-2.0414.5129.22493.23
Price / Sales1.24129.34491.4898,997.00
Price / Cash1.7815.9925.8227.90
Price / Book0.533.8712.478.13
Net Income-£1.04M£132.05M£3.32B£5.89B
7 Day Performance11.75%2.12%1.87%-0.37%
1 Month Performance-30.35%2.88%8.40%0.76%
1 Year Performance-44.12%14.47%63.49%126.54%

MyHealthChecked Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MHC
MyHealthChecked
N/AGBX 7.66
-1.2%
N/A-39.3%£3.98M£3.22M-2.0416Gap Up
AVO
Advanced Oncotherapy
N/AN/AN/AN/A£9.50MN/A-25.003,900Gap Down
RUA
RUA Life Sciences
N/AGBX 11.10
-2.4%
N/A-20.4%£6.89M£4.11M-2.6148Gap Down
SUN
Surgical Innovations Group
N/AGBX 0.58
+0.9%
N/A+2.7%£5.41M£11.92M-371.7980News Coverage
POLX
Polarean Imaging
N/AGBX 0.41
+2.0%
N/A-68.4%£4.93M£2.56M-408.0028Gap Down
BELL
Belluscura
N/AGBX 0.75
flat
N/AN/A£3.01M£1.80M-0.0624
MXCT
MaxCyte
N/AGBX 1.62
flat
N/A-99.4%£1.72M£35.75M-4.0580Gap Up
High Trading Volume
DEMG
Deltex Medical Group
N/AN/AN/AN/A£187K£1.76M-0.1537Gap Up
High Trading Volume
SN
Smith & Nephew
3.2342 of 5 stars
GBX 1,346.50
+0.4%
GBX 1,379.33
+2.4%
+19.4%£14.76B£7.08B48.4818,452Analyst Forecast
High Trading Volume
NIOX
NIOX Group
N/AGBX 72.40
-1.1%
GBX 90
+24.3%
+8.8%£302.54M£46M5,792.0092
EKF
EKF Diagnostics
N/AGBX 27.50
-2.0%
N/A-6.7%£123.50M£50.22M2,037.04356News Coverage
Positive News

Related Companies and Tools


This page (LON:MHC) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners